INTRODUCTION
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal (GI) disorders, characterized by chronic abdominal pain and a change in the frequency or form of stool [1] . It affects an estimated 10% to 15% of the global population [2] and carries a significant disease burden in terms of decreased productivity, increased healthcare costs and reduced health-related quality of life [3] . Despite the global prevalence of IBS, its pathophysiology remains unclear. Studies have reported disturbances in gut microbiota and persistent, subclinical systemic and mucosal inflammation in individuals with IBS [4] . Significant overlaps also exist between patients with IBS and those with dyspepsia [5] , hinting at a possible pathogenic role of Helicobacter pylori (H. pylori) in IBS. H. pylori is a prevalent gramnegative bacterium that grows in the gut of more than half of the world's population, and it is even more common in developing countries [6] . The mode of transmission of H. pylori is unclear, but believed to be fecal-oral. H. pylori, especially strains that produce cytotoxin-associated gene A (CagA) protein, causes chronic inflammation in the stomach and duodenum, microbial dysbiosis [7] as well as elevated systemic inflammation [8] . H. pylori infection has been linked to several conditions, including dyspepsia and even hyperemesis gravidarum [9] . However, its role in the pathogenesis of IBS remains largely unknown. Some studies have highlighted increased rates of H. pylori infection in patients with IBS compared to healthy controls [10, 11] , while others have disputed this and found no association between H. pylori infection and IBS [12] . This association has been challenged as H. pylori is thought to affect mainly the upper GI trait instead of the lower GI tract. Some also contend that the association is merely fortuitous given the widespread prevalence of H. pylori infection globally [6] . This meta-analysis thus aimed to investigate and better clarify the role of H. pylori in the pathogenesis of IBS. A better understanding of the pathogenesis of IBS has important clinical implications. 
MATERIALS AND METHODS

RESULTS
The literature search and abstraction process (and reasons for exclusion) was detailed in Figure 1 . The key details of each study were extracted and summarized in Table  1 [10-22] . A total of 13 studies were systematically reviewed. Four studies were excluded from the final meta-analysis as three did not have a control group while one did not detect H. pylori infection in either patients with IBS or healthy controls, hence no OR could be calculated. As seen in Figure 2 , the studies had an overall high degree of heterogeneity (I2 = 87.38%), likely due to the different study designs and method of detection of H. pylori employed. Random-effects meta-analysis found that patients with IBS did not have a significantly increased likelihood of H. pylori infection, as the pooled OR was 1.47 (95%CI: 0.90-2.40, P = 0.123). Separate subgroup analyses and sensitivity analyses were likely underpowered and hence, were not conducted due to the small number of studies available. With regard to the possibility of publication bias, visual inspection of the funnel plot revealed a roughly symmetrical distribution of studies ( Figure 3 ) and encouragingly, Egger test was not significant for publication bias (P = 0.189).
DISCUSSION
Overall, current evidence suggests that patients with IBS may have an increased likelihood of H. pylori infection, but this is not statistically significant (pooled OR 1.47, 95%CI: 0.90-2.40, P = 0.123). It must also be acknowledged that all of the available studies reported only crude odd ratios and did not adjust for potential confounders, further weakening any potential association between IBS and H. pylori infection. To the best of our knowledge, this review is the first to examine the association between IBS and H. pylori infection. The current meta-analysis is therefore a novel and significant contribution to current literature.
It is well demonstrated that H. pylori infection leads to chronic inflammation and is involved in the etiopathogenesis of atrophic gastritis, intestinal metaplasia and peptic ulcers [23] . Patients with IBS have been found to have increased lamina propria immune cells in the colonic mucosa [24] and significantly reduced levels of oleoylethanolamide (a fatty acid amide with anti-inflammatory properties) when compared to healthy controls [25] . These are suggestive of chronic, subclinical inflammation at the microscopic level [26] . Increased infiltration of mucosal mast cells have also been reported in the GI tract of patients with IBS when compared to healthy controls [27] . In considering the possible pathogenic mechanisms of H. pylori in relation to IBS, H. pylori infection has been associated with elevated inflammatory markers [8] , increased mast cell activation [28] and gastric mucosal and neural remodeling [29] . Vacuolating cytotoxin A [30] and the neutrophil-activating protein [28] of H. pylori are both potent mast cell stimulators. Although a definite and consistent pattern of immune dysregulation has yet to be established in patients with IBS, increased mast cell activation and immune activity in the gut may correlate with symptoms of visceral hypersensitivity [31] . Furthermore, in a study utilizing the rectal barostat to elicit abdominal symptoms in patients with IBS, positive results were seen almost exclusively in H. pylori-positive patients with IBS, suggesting a potential role of H. pylori in stimulating visceral hypersensitivity [16] . Preclinical and clinical studies have often reported a link between increased intestinal mucosal inflammation and changes in sensory-motor function [32, 33] . As such, H. pylori infection may result in gastric dysmotility and neuroplastic changes in the afferent neural pathways, giving rise to visceral hypersensitivity and prototypical IBS symptoms.
On the other hand, contrary findings have also been reported. A study on patients with functional dyspepsia found no association between H. pylori infection and increased pain perception of gastric distension [34] . Studies that investigated the effect of H. pylori eradication therapy on IBS symptoms also found no significant differences at follow-up [11, 21] . However, the relationship is difficult to analyse as it may be confounded by the fact that H. pylori is eradicated with antibiotics, which is also associated with a significantly increased risk of developing IBS [35] and may also aggravate IBS symptoms [36] . A fundamental understanding of the pathogenesis of IBS is still lacking. Additionally, psychological factors such as stress, depression and anxiety are known to contribute to the pathogenesis [37] . Our study investigated another potential contributory factor. Patients with IBS may have an increased likelihood of H. pylori infection albeit this is not statistically significant. The role of H. pylori eradication therapy is also unclear as it does not appear to improve IBS symptoms in the limited studies available.
Other limitations of current evidence that must be discussed include the fact that some of the available studies [13, 18] used a self-report symptom questionnaire in the diagnosis of IBS. There is a known wide variability in the definition of constipation and diarrhoea [38] , and the subjectivity and inter-study variability in the diagnosis of IBS could further affect the reliability of current findings. Also, some of the studies [13, 18] included in the meta-analysis did not investigate study participants for organic disease that may contribute to IBS-like symptoms. Limited studies also performed CagA testing. In one study [18] , CagA antibody positivity but not H. pylori seropositivity was found to be significantly associated with IBS. Future studies should examine the effect of CagA positivity as the CagA toxin is an important H. pylori virulence factor associated with a greater inflammatory response [39] . There was also a significant degree of heterogeneity amongst the various studies included in the meta-analysis (I2 = 87.38%). This could stem from the subjectivity and different definitions used in the diagnosis of IBS as previously discussed, as well as the differing tests used to detect H. pylori infection, e.g., serum IgG antibodies, urea breath test and stool antigen assay. Moreover, the commonly-used serologic test is unable to distinguish between current and previous H. pylori infection as it remains positive for years, even after H. pylori eradication therapy [40] . Although some studies carefully selected only individuals who have no history of previous H. pylori eradication therapy [16] , it was less clear in other studies. The duration of H. pylori infection may also affect our analysis as study subjects with more longstanding infection may have greater mucosal inflammation and more significant GI symptoms.
Last but not least, the influence of H. pylori on the composition of distal gut microbiota is an important area that deserves further study. Microbial dysbiosis is a known hallmark of IBS [41] . However, it is unclear how H. pylori, which is thought to affect mainly the upper GI tract, may affect the lower GI tract [42] . In conclusion, current evidence does not support an association between IBS and H. pylori infection. Patients with IBS may have a slight increased likelihood of H. pylori infection albeit this is not statistically significant. This relationship is complicated by admittedly problematic study designs and potential confounding factors. The role of H. pylori eradication therapy also remains unclear as it does not appear to improve IBS symptoms. Further rigorous and detailed studies with larger sample sizes, carefully selected subjects, and after H. pylori eradication therapy are warranted. The influence of H. pylori on gut microbiota should also be investigated. 
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